A nephroprotective iodinated contrast agent with cardioprotective properties: A pilot study

Elizabeth S. Rowe1 | Vernon D. Rowe1 | John Hunter1 | Michael R. Gralinski2 | Liomar A. Neves2

1 Neurrow Pharmaceuticals, Inc, Shawnee, Kansas, USA
2 CorDynamics, Inc, Chicago, Illinois, USA

Correspondence
Elizabeth S. Rowe, PhD, MBA, Neurrow Pharmaceuticals, Inc, 6415 Hillside St, Shawnee, KS 66218, USA. Email: erowe@neurokc.com

Abstract

Background and Purpose: Evaluation and treatment of acute ischemic syndromes, in the heart and brain, require vessel visualization by iodinated X-ray contrast agents. However, these contrast agents can induce injury, in both the kidneys and target organs themselves. Sulfobutylether beta cyclodextrin (SBECD) added to iohexol (SBECD-iohexol) (Captisol Enabled-iohexol, Ligand Pharmaceuticals, Inc, San Diego, CA) is currently in clinical trials in cardiovascular procedures, to determine its relative renal safety in high-risk patients. Preclinical studies showed that SBECD-iohexol reduced contrast-induced acute kidney injury in rodent models by blocking apoptosis. The current study was undertaken to determine whether SBECD-iohexol is also cardioprotective, in the male rat ischemia-reperfusion model, compared to iohexol alone.

Methods: After anesthesia, the left coronary artery was ligated for 30 min and the ligation released and reperfusion followed for 2 h prior to sacrifice. Groups 1–4 were injected in the tail vein 10 min prior to ischemia with: (1) vehicle; (2) iohexol; (3) SBECD; and (4) SBECD-iohexol. Infarct size, hemodynamics, and serum markers were measured.

Results: An eight-fold increase in serum creatine kinase in the iohexol-alone group was observed, compared with no increase in the SBECD-iohexol group. The mean arterial pressure and rate pressure product were depressed in the iohexol-alone group, but not in the SBECD-iohexol group, or controls. No difference in infarct size or serum creatinine among the groups was observed.

Conclusion: The results of this study suggest that SBECD-iohexol is superior to iohexol alone, for both the preservation of cardiomyocyte integrity and preservation of myocardial function in myocardial ischemia.

KEYWORDS

cardiotoxicity of contrast, contrast for interventional procedures, iodinated contrast safety, protection from contrast, safe

INTRODUCTION

The diagnosis and treatment of acute ischemic syndromes, both in the heart and brain, require the intra-arterial injection of iodinated X-ray contrast agents for vessel visualization. However, these contrast agents can have deleterious side effects, both on the kidneys as the agents are cleared from the body, and on the target organs themselves.1–6 There clearly is a need for an iodinated contrast agent that is safer for both the kidneys and target organs of visualization, including both the heart and brain.

The importance of endovascular procedures in the treatment of large vessel intracranial proximal arterial occlusion in acute
ischemic stroke is now well established.\textsuperscript{7–17} Multiple modifiable factors, however, can affect the outcomes of patients undergoing these procedures.\textsuperscript{18–23} The neurotoxicity of iodinated contrast has long been recognized. Encephalopathy occasionally occurs as a complication of coronary and brain angiography.\textsuperscript{4,5,24–34} While encephalopathy is relatively rare, the known neurotoxicity of contrast for neuronal tissue could play a role during angiographic procedures in more subtle ways.

Acute kidney injury induced by contrast agents (CI-AKI) occurs in a significant number of interventional cardiology procedures in high-risk patients. In addition, a recent report suggests that 13% of patients undergoing elective diagnostic coronary angiography show elevated serum troponin T levels in the absence of clinical or other signs of procedural ischemia, and that the volume of contrast agent used was an independent predictor of that elevation.\textsuperscript{35}

Thus, multiple organ systems, including those that are the targets of vascular visualization, can be vulnerable to exposure to iodinated contrast agents, highlighting the need for safer such agents.

As we previously reported in this journal, SBECO (trade name Captisol, Ligand Pharmaceuticals, Inc, San Diego, CA) was shown to mitigate CI-AKI in laboratory animals.\textsuperscript{36} A reformulation of iohexol with SBECO is now in phase II clinical trials in the United States, for prevention of CI-AKI in vulnerable patients undergoing elective coronary angiography. This trial is intended to determine whether those nephroprotective properties of the reformulation, found in multiple species of laboratory animals, can be translated to the clinic. SBECO is widely used in marketed drug formulations to increase solubility, including remdesivir, one of the few approved treatments for Covid-19.\textsuperscript{37} However, in our studies, only one molecule of SBECO per 40 molecules of iohexol is necessary for nephroprotection, ruling out a solubilization mechanism in this case.\textsuperscript{36}

We previously showed that the mechanism by which this nephroprotective effect was achieved was the inhibition of contrast-induced apoptosis in renal cell tissue culture.\textsuperscript{36} Since apoptosis plays a major role in myocardial ischemic tissue damage,\textsuperscript{38–40} we wondered whether SBECO-iohexol might protect the ischemic myocardium in a rat model of myocardial ischemia–reperfusion. In short, we wondered whether SBECO-iohexol might be cardioprotective as well as nephroprotective.

If it is cardioprotective, SBECO-iohexol could be neuroprotective as well, since apoptosis also plays a major role in tissue damage in acute ischemic stroke.\textsuperscript{41–43} Since multiple modifiable risk factors can lead to improved stroke outcomes, it is possible that the use of a safer iodinated contrast agent could further improve stroke outcomes for patients undergoing endovascular evaluation and treatment.

**METHODS**

**Materials**

SBECO (trade name Captisol, Ligand Pharmaceuticals, Inc) and iohexol (Omnipaque 300, GE) were used in the concentrations shown in Table 1.

**Experimental procedure**

The rat ischemia/reperfusion model has been well established and is a widely used animal model for studying myocardial ischemia.\textsuperscript{44,45} A total of 24 male Sprague–Dawley rats (0.318–0.354 kg) were used in this pilot study and allocated into five groups, see Table 1.

All rats were anesthetized via an intraperitoneal injection of Nembutal. Anesthetic plane was maintained by administering additional half doses of Nembutal as needed. Once consciousness was lost, the trachea was isolated for mechanical ventilation with room air. Depth of anesthesia was monitored throughout the experiment by observing the toe pinch reflex at least every 15 min. Animal body temperature was maintained at approximately 37°C throughout the procedure. A lead II electrocardiogram was monitored throughout the experiment via electrodes placed in the skin of the right arm, left leg and chest of the animal. An indwelling catheter was placed into the left jugular vein for collection of a blood sample, and another indwelling catheter was placed into a lateral tail vein for test compound administration. A femoral artery was cannulated for measurement of systemic arterial pressure by Millar catheter. Left thoracotomy (through the fourth intercostal space) and pericardiotomy were performed. A 6-0 silk suture was introduced around the left anterior descending coronary artery (LAD) midway between atria and apex. A small piece of plastic tubing (PE50) that was larger in diameter than the artery was placed on top of the artery and left in place until induction of ischemia.

Hemodynamic parameters were monitored during the approximately 10-min equilibration period. After hemodynamic parameters reached steady-state, animals were monitored for 10 min to establish baseline values. After the baseline period, animals in Groups 1–4 received an intravenous infusion of either vehicle or test article (Figure 1) into the tail vein over a 2-min period; animals were monitored for an additional 8 min. At the end of the dose monitoring period for animals in Groups 1–4, or at the end of baseline for animals in Group 5, the suture was secured around both the tubing and the artery to totally occlude the left LAD and induce ischemia. The tubing was removed after 30 min of ischemia to initiate the 120-min reperfusion period. Animals in Group 5 received an intravenous infusion of the test article into the tail vein over a 2-min period at the beginning of reperfusion. Refer to Figure 1 for further details.

Blood samples were obtained from the jugular vein cannula following the ischemia/reperfusion period and serum levels of creatine kinase (CPK) and creatinine determined.

Infarct size was determined by staining the hearts with India Ink/2,3,5-triphenyltetrazolium chloride (TTC). Briefly, while rats were still anesthetized, hearts were religated and India ink was injected via a tail vein until normally perfused myocardium was adequately stained. Hearts were then removed and sectioned transversely into 1 mm thick slices. The right ventricle, apex, and atria were discarded, and the left ventricle slices were incubated at 37°C for 10–15 min in a 1% TTC in phosphate buffered saline. TTC solution stains the area at risk (AAR) for infarction with a reddish color and the infarcted tissues appear pale yellow. After staining, heart slices were transferred to 10% neutral
TABLE 1  Rat model of ischemia/reperfusion injury study design

A- Treatments

Group 1: Vehicle (sterile saline for injection 5 ml/kg, U.S.P.; n=4)  
Group 2: Iohexol 1500 mg/kg (n=4)  
Group 3: SBEDC 225 mg/kg (n=3)  
Group 4: Iohexol 1500 mg/kg + SBEDC 225 mg/kg (n=6)  
Group 5: Iohexol 1500 mg/kg + SBEDC 225 mg/kg (n=5)

B- Study Design – Ischemia/Reperfusion

| Groups 1 to 4 | 10 minutes | 10 minutes | 30 minutes | 240 minutes |
|---------------|------------|------------|------------|-------------|
| Instrumentation — Equilibration | Baseline | * Post-Dose | Ischemia | Reperfusion |

| Group 5 | 10 minutes | 30 minutes | 240 minutes |
|---------|------------|------------|-------------|
| Instrumentation — Equilibration | Baseline | Ischemia | # Reperfusion |

* Dosed over 2 min and monitored for 8 min post-dose  
# Dose over 2 min starting at the beginning of reperfusion  
◊ Blood samples obtained in the last minute of reperfusion  
○ Hearts were religated, stained with India ink, and removed  
n Number of animals in a group  
Note: All animals underwent coronary artery occlusion for 30 min followed by 2 h of reperfusion. Rats were treated, according to the indicated schedule, with vehicle (saline 5 ml/kg, Group 1), iohexol (1500 mg/kg, Group 2), sulfobutylether beta cyclodextrin (SBEDC) (225 mg/kg, Group 3), or a combination of SBEDC-iohexol (1500–225 mg/kg, Groups 4 and 5).

Buffered formalin for at least 24 h and then placed between two glass slides. Both sides of the slide were scanned using a flatbed scanner and scanned images were digitized and analyzed using Image J 1.46r software. Group 5 animals, not shown here, which received SBEDC-iohexol after ligation rather than before, tracked with the vehicle group 1.

RESULTS

Hemodynamic parameters

Figure 1A shows a graph of mean arterial pressure (MAP) for Groups 1–4, showing that all groups declined throughout the study prior to sacrifice. However, MAP for the animals in the SBEDC-iohexol group tracked much closer to the vehicle group than did the animals receiving iohexol alone, even in the preischemic phase of the study.

Figure 1B shows a graph of the rate–pressure product (RPP) for Groups 1–4. This measurement is held to be a surrogate measure of myocardial oxygen consumption and cardiac workload. The RPP for the iohexol alone group tracked considerably lower than the group treated with SBEDC-iohexol, which was similar to the other two groups, even during the pre-ischemic phase of the study.

Clinical chemistry

Creatine kinase

The bar graph in Figure 2A shows the results obtained for serum CPK values immediately prior to sacrifice. An eight-fold increase in the mean serum CPK value was seen in the iohexol alone group versus all other groups, including the SBEDC-iohexol group. This suggests significant damage to ischemic cardiomyocytes. This cardiomyocyte damage was significantly mitigated in the SBEDC-iohexol group.

Creatinine

Figure 2B shows the results of serum creatinine measured immediately prior to sacrifice. All the groups had values that were within the error of the measurement, to be expected for this short-duration study.
FIGURE 1  Mean arterial pressure (MAP) (A) and rate pressure product (RPP) (B) in the rat model of ischemia/reperfusion (30 min/2 h) injury. Rats were treated with vehicle (saline, Group 1; \( n = 4 \)), iohexol (1500 mg/kg, Group 2; \( n = 4 \)), sulfobutylether beta cyclodextrin (SBECD) (225 mg/kg, Group 3; \( n = 3 \)), or a combination of SBECD-iohexol (1500–225 mg/kg, Group 4; \( n = 6 \)). Animals in Groups 1–4 received an intravenous infusion of either vehicle or test article into the tail vein over a 2-min period after the baseline (BL) period. Animals were monitored for the duration of the study. Values are expressed as mean ± standard deviation.

Infarct size

The AAR for each group is shown in Figure 3A. This represents the percentage of the left ventricular volume that experienced ischemia during coronary artery ligation. Figure 3B shows the percentage of the AAR determined to be infarcted. With the small number of animals in each group in this pilot study, the differences among the groups did not reach statistical significance for infarct size. However, the wide range of values for Group 4, the SBECD-iohexol group, suggests that some animals in that group did have a smaller infarct size than those in the other groups.

DISCUSSION

The safety of FDA-approved iodinated contrast agents for clinical procedures involving X-ray technology, and the necessity of their use in modern clinical medicine, is generally accepted. But since these agents can cause kidney injury in vulnerable patients, and since these vulnerable patients are frequently the ones who require intravascular injection of contrast, considerable effort has gone into reducing the risk of this complication. Thus, SBECD-iohexol, now in clinical trials, could represent a major improvement in the safe use of iodinated contrast in vulnerable populations, based on a reduction of
CI-AKI alone. This benefit would apply to all uses of iodinated contrast, including in endovascular diagnosis and therapy by neurologists, radiologists, interventional radiologists, neuroradiologists, as well as cardiologists. In addition, it is possible that SBEC-D-iohexol can improve clinical outcomes in other ways. For instance, in the current study, there was an eight-fold increase in serum creatine kinase in the animals treated with iohexol alone compared to the group receiving SBEC-D-iohexol. Likewise, there was diminished cardiac function in the iohexol-alone group compared to the SBEC-D-iohexol group. This suggests that adding SBEC-D to iohexol, in the proper ratio, is cardioprotective for ischemic heart tissue, an addition to its nephroprotective effects.

In animal models of brain ischemia, produced by ischemia/reperfusion and cardiac arrest/reperfusion, as well as in direct brain ischemia models, apoptosis has been shown to be an important factor in ultimate tissue damage. We previously showed that iodinated contrast agents, including iohexol (Omnipaque, GE), iodixanol (Visipaque, GE), and iopromide (Ultravist, Bayer), induced apoptosis in cultured HK-2 cells, and that for all of these agents, the addition of SBEC-D in the appropriate ratio blocked that apoptosis. Thus, it is...
### Figure 3

Myocardial infarction in the rat model of ischemia/reperfusion (30 min/2 h) injury. (A) Area at risk (AAR; % of left ventricle [LV]) and (B) infarct size (IZ, % AAR) in rats treated with vehicle (saline, Group 1), iohexol (1500 mg/kg, Group 2), sulfobutylether beta cyclodextrin (SBECD) (225 mg/kg, Group 3), or a combination of SBECD-iohexol (1500–225 mg/kg, Groups 4 and 5). Animals in Groups 1–4 received an intravenous infusion of either vehicle or test article into the tail vein over a 2-min period after the baseline period; animals were then monitored for an additional 8 min prior to initiation of ischemia. Animals in Group 5 received an intravenous infusion of the test article into the tail vein over a 2-min period at the beginning of reperfusion. Values are expressed as mean ± standard deviation. n = number of animals in each group.

---

reasonable to hypothesize that SBECD-iohexol might be protective for the brain in acute ischemic stroke as well.

The toxicity of iodinated contrast agents for many cell types has been widely studied (brain, intervertebral disc, and cardiomyocytes), though renal cells have received the most attention. For example, in a recent study of patients undergoing elective coronary angiography, 13% of asymptomatic patients exhibited an increase in troponin T, indicating cardiomyocyte damage after a purely diagnostic coronary angiogram. The volume of contrast used was an independent variable predicting this elevation. No appreciable difference among several iodinated contrast agents was noted.

Neurologic complications, including encephalopathy, can occur after myocardial infarction and coronary intervention, without obvious arterial occlusion. Encephalopathy may be related to the volume of contrast used.

In a general way, the apoptotic process appears to be present in many chronic neurodegenerative processes as well as the more acute syndromes mentioned above. Because of this, there have been many attempts to identify agents and methods to reduce apoptosis in brain, heart, and other vulnerable tissues. Whether or not reformulations with SBECD will affect these diseases must await further study.
In conclusion, the results of this study suggest that SBEC-D-iohexol is superior to iohexol alone, for both the preservation of cardiomyocyte integrity and preservation of myocardial function in myocardial ischemia. Further studies of this new contrast agent in additional tissues, particularly in neuronal tissue, are warranted. If the current clinical trials of SBECD-iohexol (Captisol Enabled-iohexol, Ligand Pharmaceuticals, Inc) are successful and this new contrast agent is approved, it may contribute to improved outcomes, not only in cardiovascular procedures, but also in neurointerventional procedures.

ACKNOWLEDGMENTS AND DISCLOSURE

V. Rowe is author of patent US 8,277,779 B2 on SBECD-iohexol and is entitled to royalties from future sales if any of CE-iohexol; M.R. Gralinksi is CEO and Founder of CorDynamics, Inc; Liomar A. Neves is an employee of CorDynamics.

ORCID

Elizabeth S. Rowe https://orcid.org/0000-0002-9319-4048

REFERENCES

1. McCullough PA, Adam A, Becker CR, et al. Risk prediction of contrast-induced nephropathy. Am J Cardiol 2006;98:27K-36K.
2. Chalikias G, Drosos I, Tziakas DN. Contrast-induced acute kidney injury: an update. Cardiovasc Drugs Ther 2016;30:215-28.
3. McCullough PA, Stacul F, Becker CR, et al. Contrast-induced nephropathy (CIN) consensus working panel: executive summary. Rev Cardiovasc Med 2006;7:177-97.
4. Kocabay G, Karabay CY, Kalayci A, et al. Contrast-induced neurotoxicity after coronary angiography. Herz 2014;39:522-7.
5. Junck L, Marshall WH. Neurotoxicity of radiological contrast agents. Ann Neurol 1983;13:469-84.
6. McCullough P. Outcomes of contrast-induced nephropathy: experience in patients undergoing cardiovascular intervention. Catheter Cardiovasc Interv 2006;67:335-43.
7. Berkhemer OA, Fransen PS, Beumer D, et al. Randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 2015;372:1019-30.
8. Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 2015;372:1019-30.
9. Campbell BC, Mitchell PJ, Yan B, et al. A multicenter, randomized, controlled study to investigate extending the time for thrombolysis in the treatment of acute ischemic stroke. N Engl J Med 2015;372:418-29.
10. Molina CA, Chamorro A, Rovira À, et al. Revascularization: the need for Interventional procedures, but also in neurointerventional procedures.
11. Saever JL, Goyal M, Bonafe A, et al. Solitaire™ with the intention for thrombectomy as primary endovascular treatment for acute ischemic stroke (SWIFT PRIME) trial: protocol for a randomized, controlled, multicenter study comparing the solitaire revascularization device with IV tPA with IV tPA alone in acute ischemic stroke. Int J Stroke 2015;10:439-48.
12. Hacke W. Interventional thrombectomy for major stroke—a step in the right direction. N Engl J Med 2015;372:76-7.
13. Zaidat OO, Castonguay AC, Nogueira RG, et al. Trevo stent-retriever mechanical thrombectomy for acute ischemic stroke secondary to large vessel occlusion registry. J Neurointerv Surg 2018;10:516-24.
14. Liaw N, Liebeskind D. Emerging therapies in acute ischemic stroke. F1000Res 2020;9:546-54.
15. Bhatia K, Bhagavan S, Bains N, et al. Current endovascular treatment of acute ischemic stroke. Mo Med 2020;117:480-9.
16. Qureshi AI, Baskett WI, Huang W, et al. Acute ischemic stroke and covid-19: an analysis of 27,676 patients. Stroke 2021;52:905-12.
17. Malisch TW, Zaidat OO, Castonguay AC, et al. Clinical and angiographic outcomes with the combined local aspiration and retriever in the North American Solitaire Stent-Retriever Acute Stroke (NASA) registry. Interv Neurol 2018;7:26-35.
18. Mulder M, Jansen IGH, Goldhoorn RB, et al. Time to endovascular treatment and outcome in acute ischemic stroke: Mr clean registry results. Circulation 2018;138:232-40.
19. Chalos V, LeCouffe NE, Uyttenboogaart M, et al. Endovascular treatment with or without prior intravenous alteplase for acute ischemic stroke. J Am Heart Assoc 2019;8:e011592.
20. Mulder MJ, Berkhemer OA, Fransen PS, et al. Treatment in patients who are not eligible for intravenous alteplase: Mr clean subgroup analysis. Int J Stroke 2016;11:637-45.
21. Treurniet KM, Berkhemer OA, Imminik RV, et al. A decrease in blood pressure is associated with unfavorable outcome in patients undergoing thrombectomy under general anesthesia. J Neurointerv Surg 2018;10:107-11.
22. van den Berg LA, Koeliman DL, Berkhemer OA, et al. Type of anesthesia and differences in clinical outcome after intra-arterial treatment for ischemic stroke. Stroke 2015;46:1257-62.
23. Beumer D, van Bokel TH, Schipperen S, et al. The relationship between interventionists’ experience and clinical and radiological outcome in intra-arterial treatment for acute ischemic stroke. Am J Cardiac Catheterey 2017;377:97-101.
24. Law S, Panichpikal D, Demede M, et al. Contrast-induced neurotoxicity following cardiac catheterization. Case Rep Med 2012:1-4.
25. Spina R, Simon N, Markus R, et al. Contrast-induced encephalopathy following cardiac catheterization. Catheter Cardiovasc Interv 2017;90:257-68.
26. Frontera JA, Pile-Spellman J, Mohr JP. Contrast-induced neurotoxicity and selective cortical injury. Cerebrovasc Dis 2007;24:148-51.
27. Kariyanna PT, Aurora L, Jayarangalaiah A, et al. Neurotoxicity associated with radiological contrast agents used during coronary angiography: a systematic review. Am J Med Case Rep 2020;8:60-6.
28. Torvik A, Walday P. Neurotoxicity of water-soluble contrast media. Acta Radiol Suppl 1995;399:221-9.
29. Cailié JM, Gioux M, Arné P, et al. Neurotoxicity of nonionic iodinated water-soluble contrast media in myelography: experimental study. A JR N Am J Neuroradiol 1983;4:1185-9.
30. Cailié JM, Allard M. Neurotoxicity of hydrosoluble iodine contrast media. Invest Radiol 1988;23(Suppl 1):S210-2.
31. Yu J, Dangas G. Commentary: new insights into the risk factors of contrast-induced encephalopathy. J Endovasc Ther 2011;18:545-6.
32. Guimaraens L, Vivas E, Fonnegra A, et al. Transient encephalopathy following contrast media. Invest Radiol 1988;23(Suppl 1):S210-2.
33. Onishi S, Sakamoto S, Okazaki T, et al. Iodinated contrast-induced encephalopathy after coil embolization of unruptured aneurysms. Asian J Neurosurgery 2018;13:858-60.
34. Nakao K, Yoshi G, Hirose Y, et al. Rare cases of contrast-induced encephalopathies. Asian J Neurosurgery 2020;15:786-93.
35. Kreutzinger P, Wildi K, Twenerbold R, et al. Incidence and predictors of cardiomyocyte injury in elective coronary angiography. Cerebrovasc Dis 2017;43:140-5.
36. Rowe ES, Rowe BD, Biswas S, et al. Preclinical studies of a kidney safe iodinated contrast agent with cardioprotective properties. J Neuroimaging 2016;26:511-8.
immune stabilization strategy for SARS-CoV-2 induced ‘panic’ attack. J Neurol Sci 2020;415:116935.
38. Takemura G, Kanoh M, Minatoguchi S, et al. Cardiomyocyte apoptosis in the failing heart—a critical review from definition and classification of cell death. Int J Cardiol 2013;167:2373-86.
39. Fliss H, Gattinger D. Apoptosis in ischemic and reperfused rat myocardium. Circ Res 1996;79:949-56.
40. Del Re DP, Angalan D, Linkermann A, et al. Fundamental mechanisms of regulated cell death and implications for heart disease. Physiol Rev 2019;99:1765-817.
41. Radak D, Katsiki N, Resanovic I, et al. Apoptosis and acute brain ischemia in ischemic stroke. Curr Vasc Pharmacol 2017;15:115-22.
42. Orellana-Urzúa S, Rojas I, Libano L, et al. Pathophysiology of ischemic stroke: role of oxidative stress. Curr Pharm Des 2020;26:4246-60.
43. Yang JL, Mukda S, Chen SD. Diverse roles of mitochondria in ischemic stroke. Redox Biol 2018;16:263-75.
44. Wu Y, Yin X, Wijaya C, et al. Acute myocardial infarction in rats. J Vis Exp 2011;48:1-4.
45. Lindsey ML, Bolli R, Canty JM, Jr., et al. Guidelines for experimental models of myocardial ischemia and infarction. Am J Physiol Heart Circ Physiol 2018;314:H812-H838.
46. Kim KH, Park JY, Park HS, et al. Which iodinated contrast media is the least cytotoxic to human disc cells? Spine J 2015;15:1021-7.
47. Chai CM, Rasmussen H, Eriksen M, et al. Predicting cardiotoxicity propensity of the novel iodinated contrast medium GE-145: ventricular fibrillation during left coronary arteriography in pigs. Acta Radiol 2010;51:1007-13.
48. Mitchell AM, Molitoris BA, Teague SD. Contrast material-induced nephropathy: causation quandaries. Radiology 2015;275:928-9.
49. Zhang J, Duarte CG, Ellis S. Contrast medium- and mannitol-induced apoptosis in heart and kidney of SHR rats. Toxicol Pathol 1999;27:427-35.
50. Wu Y, Chen M, Jiang J. Mitochondrial dysfunction in neurodegenerative diseases and drug targets via apoptotic signaling. Mitochondrion 2019;49:35-45.
51. Radi E, Formichi P, Battisti C, et al. Apoptosis and oxidative stress in neurodegenerative diseases. J Alzheimers Dis 2014;42(Suppl 3):5125-52.
52. Ghavami S, Shojaei S, Yeganeh B, et al. Autophagy and apoptosis dysfunction in neurodegenerative disorders. Prog Neurobiol 2014;112:24-49.
53. Chi H, Chang HY, Sang TK. Neuronal cell death mechanisms in major neurodegenerative diseases. Int J Mol Sci 2018;19:3082.
54. Lv J, Guan W, You Q, et al. RIPC provides neuroprotection against ischemic stroke by suppressing apoptosis via the mitochondrial pathway. Sci Rep 2020;10:5361.
55. Waldmeier PC, Tatton WG. Interrupting apoptosis in neurodegenerative disease: potential for effective therapy? Drug Discov Today 2004;9:210-8.
56. Ji ZH, Zhao H, Liu C, et al. In-vitro neuroprotective effect and mechanism of 2β-hydroxy-δ-cadinol against amyloid β-induced neuronal apoptosis. Neuroreport 2020;31:245-50.
57. Zheng JH, Xie L, Li N, et al. Pd98059 protects the brain against mitochondrial-mediated apoptosis and autophagy in a cardiac arrest rat model. Life Sci 2019;232:116618.
58. Rivers JR, Maggo SD, Ashton JC. Neuroprotective effect of hydroxypropyl-beta-cyclodextrin in hypoxia-ischemia. Neuroreport 2012;23:134-8.

How to cite this article: Rowe ES, Rowe VD, Hunter J, Gralinski MR, Neves LA. A nephroprotective iodinated contrast agent with cardioprotective properties: A pilot study. Journal of Neuroimaging, 2021;31:706–713. https://doi.org/10.1111/jon.12873